Advertisement
Canada markets open in 8 hours 46 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7304
    +0.0007 (+0.09%)
     
  • CRUDE OIL

    82.92
    +0.11 (+0.13%)
     
  • Bitcoin CAD

    88,007.10
    -3,369.11 (-3.69%)
     
  • CMC Crypto 200

    1,386.12
    -37.98 (-2.67%)
     
  • GOLD FUTURES

    2,325.10
    -13.30 (-0.57%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,460.50
    -204.00 (-1.15%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,695.21
    -764.87 (-1.99%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

COVID-19: Delta Plus still 'variant of interest', 40 cases reported so far in India, say govt sources

Representative Image
Representative Image

New Delhi [India], June 23 (ANI): A total of 40 cases of Delta Plus variant of COVID-19 coronavirus has been detected in the country, government sources informed on Wednesday, adding that most of the infections were from Maharashtra, Madhya Pradesh, Kerala, and Tamil Nadu.

Sources said that the Delta Plus variant is still a "variant of interest".

However, according to the Union Health Ministry, INSACOG has informed that the Delta Plus Variant is currently a "Variant of Concern (VOC)" and it has characteristics of increased transmissibility, stronger binding to receptors of lung cells and potential reduction in monoclonal antibody response.

ADVERTISEMENT

Based on the recent findings of INSACOG, the Union Health Ministry has alerted and advised Maharashtra, Kerala and Madhya Pradesh regarding the Delta Plus variant of COVID-19.

INSACOG, a consortium of 28 laboratories of the Ministry of Health and Family Welfare, Department of Biotechnology, Indian Council of Medical Research (ICMR) and Council of Scientific and Industrial Research (CSIR), has informed that the Delta Plus Variant, currently a Variant of Concern (VOC), has the following characteristics: Increased transmissibility; Stronger binding to receptors of lung cells and Potential reduction in monoclonal antibody response. (ANI)